Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Zollinger-Ellison Syndrome 1Gastroesophageal Reflux 1Barrett Esophagus 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × YF 476 × Clear all
NCT02597712 2021-04-12

YF476 in Barrett's Esophagus

Trio Medicines Ltd.

Phase 2 Completed
27 enrolled 15 charts
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux

NCT02454075 2021-01-29

YF476 and Type II Gastric Carcinoids

Trio Medicines Ltd.

Phase 2 Terminated
3 enrolled 11 charts

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡